Week in Review: Tigermed, a Hangzhou CRO, Plans IPO  
8/6/2012 9:51:41 AM

by Richard Daverman, PhD

August 4, 2012 -- Tigermed Consulting, the clinical-stage CRO headquartered in Hangzhou, will stage an IPO on the ChiNext exchange, with pricing expected August 6; Covidien officially opened its China medical device R&D facility in Shanghai’s Caohejing Hi-Tech Park; Luqa Pharma of Hong Kong in-licensed China rights to a scar treatment from Stratpharma, a Swiss company; Kinex Pharma, a New York-state startup developing cancer drugs, received an investment from Dr. Manson Fok of Hong Kong; Barclays Bank raised its rating for the China healthcare space, moving to Positive on the sector; and Roche will hire an additional 1,000 people in China over the next year, as the company’s China revenues continue to climb. More details….

Stock Symbols: (NYSE: COV) (VX: ROG)